Loading…
Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa
Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administ...
Saved in:
Published in: | International journal of clinical pharmacy 2016-02, Vol.38 (1), p.70-79 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3 |
container_end_page | 79 |
container_issue | 1 |
container_start_page | 70 |
container_title | International journal of clinical pharmacy |
container_volume | 38 |
creator | Cotrina-Luque, Jesús Gil-Navarro, Maria Victoria Acosta-García, Héctor Alfaro-Lara, Eva Rocío Luque-Márquez, Rafael Beltrán-García, Margarita Bautista-Paloma, Francisco Javier |
description | Background
There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion.
Objective
The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to
Pseudomonas aeruginosa
.
Setting
Multicenter clinical trial with 11 third level Spanish hospitals.
Method
Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II).
Main outcome measure
Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported.
Results
78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported.
Conclusion
Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups. |
doi_str_mv | 10.1007/s11096-015-0208-y |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1792381530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3937133541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</originalsourceid><addsrcrecordid>eNqNkUFrHSEQx6U0NCHNB8ilLPTSyyYzurrrsTyaNhDopT2Lq24w7OpW3ZbXT18fLw2hEKiXmdHf_HX8E3KJcIUA_XVGBClaQN4ChaHdvyJnlCK0fY_4-ikHdkoucn6AujpBkXdvyCkVXd8NAs_Ir10MxYctbrn56VKuwYfi0uJLcaE0q19d0sbPsw_XRf-OozZFLxWatuxjqMkhd6YcCru5psQmpqYKrXXT2WbNbrNxiUHnRru03fsQs35LTiY9Z3fxGM_J95tP33Zf2ruvn293H-9a0_W8tJZNtDPA7KCt6DUKkNyOY2cHqrVwkuEojTCSSQScpql-BLdgB6k1dgiOnZMPR901xR-by0UtPhs3zzq4OrPCXlI2IGfwH2jPJHDgvKLv_0Ef4pZCHaRSAusrGA6VwiNlUsw5uUmtyS867RWCOniojh6q6qE6eKj2tefdo_I2Ls4-dfx1rAL0COR6FO5denb1i6p_ALxbqWM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1761208318</pqid></control><display><type>article</type><title>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</title><source>Springer Nature</source><creator>Cotrina-Luque, Jesús ; Gil-Navarro, Maria Victoria ; Acosta-García, Héctor ; Alfaro-Lara, Eva Rocío ; Luque-Márquez, Rafael ; Beltrán-García, Margarita ; Bautista-Paloma, Francisco Javier</creator><creatorcontrib>Cotrina-Luque, Jesús ; Gil-Navarro, Maria Victoria ; Acosta-García, Héctor ; Alfaro-Lara, Eva Rocío ; Luque-Márquez, Rafael ; Beltrán-García, Margarita ; Bautista-Paloma, Francisco Javier</creatorcontrib><description>Background
There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion.
Objective
The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to
Pseudomonas aeruginosa
.
Setting
Multicenter clinical trial with 11 third level Spanish hospitals.
Method
Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II).
Main outcome measure
Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported.
Results
78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported.
Conclusion
Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.</description><identifier>ISSN: 2210-7703</identifier><identifier>EISSN: 2210-7711</identifier><identifier>DOI: 10.1007/s11096-015-0208-y</identifier><identifier>PMID: 26474861</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject><![CDATA[Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Bacterial Load ; Cross Infection - diagnosis ; Cross Infection - drug therapy ; Cross Infection - microbiology ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Female ; Humans ; Infections ; Infusions, Intravenous ; Internal Medicine ; Intravenous therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Penicillanic Acid - administration & dosage ; Penicillanic Acid - adverse effects ; Penicillanic Acid - analogs & derivatives ; Pharmacy ; Piperacillin - administration & dosage ; Piperacillin - adverse effects ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - growth & development ; Pseudomonas aeruginosa - isolation & purification ; Pseudomonas Infections - diagnosis ; Pseudomonas Infections - drug therapy ; Pseudomonas Infections - microbiology ; Remission Induction ; Research Article ; Side effects ; Spain ; Time Factors ; Treatment Outcome ; Young Adult]]></subject><ispartof>International journal of clinical pharmacy, 2016-02, Vol.38 (1), p.70-79</ispartof><rights>Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015</rights><rights>Springer International Publishing 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</citedby><cites>FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26474861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cotrina-Luque, Jesús</creatorcontrib><creatorcontrib>Gil-Navarro, Maria Victoria</creatorcontrib><creatorcontrib>Acosta-García, Héctor</creatorcontrib><creatorcontrib>Alfaro-Lara, Eva Rocío</creatorcontrib><creatorcontrib>Luque-Márquez, Rafael</creatorcontrib><creatorcontrib>Beltrán-García, Margarita</creatorcontrib><creatorcontrib>Bautista-Paloma, Francisco Javier</creatorcontrib><title>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</title><title>International journal of clinical pharmacy</title><addtitle>Int J Clin Pharm</addtitle><addtitle>Int J Clin Pharm</addtitle><description>Background
There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion.
Objective
The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to
Pseudomonas aeruginosa
.
Setting
Multicenter clinical trial with 11 third level Spanish hospitals.
Method
Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II).
Main outcome measure
Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported.
Results
78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported.
Conclusion
Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Bacterial Load</subject><subject>Cross Infection - diagnosis</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - microbiology</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Infections</subject><subject>Infusions, Intravenous</subject><subject>Internal Medicine</subject><subject>Intravenous therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Penicillanic Acid - administration & dosage</subject><subject>Penicillanic Acid - adverse effects</subject><subject>Penicillanic Acid - analogs & derivatives</subject><subject>Pharmacy</subject><subject>Piperacillin - administration & dosage</subject><subject>Piperacillin - adverse effects</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - growth & development</subject><subject>Pseudomonas aeruginosa - isolation & purification</subject><subject>Pseudomonas Infections - diagnosis</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Pseudomonas Infections - microbiology</subject><subject>Remission Induction</subject><subject>Research Article</subject><subject>Side effects</subject><subject>Spain</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>2210-7703</issn><issn>2210-7711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkUFrHSEQx6U0NCHNB8ilLPTSyyYzurrrsTyaNhDopT2Lq24w7OpW3ZbXT18fLw2hEKiXmdHf_HX8E3KJcIUA_XVGBClaQN4ChaHdvyJnlCK0fY_4-ikHdkoucn6AujpBkXdvyCkVXd8NAs_Ir10MxYctbrn56VKuwYfi0uJLcaE0q19d0sbPsw_XRf-OozZFLxWatuxjqMkhd6YcCru5psQmpqYKrXXT2WbNbrNxiUHnRru03fsQs35LTiY9Z3fxGM_J95tP33Zf2ruvn293H-9a0_W8tJZNtDPA7KCt6DUKkNyOY2cHqrVwkuEojTCSSQScpql-BLdgB6k1dgiOnZMPR901xR-by0UtPhs3zzq4OrPCXlI2IGfwH2jPJHDgvKLv_0Ef4pZCHaRSAusrGA6VwiNlUsw5uUmtyS867RWCOniojh6q6qE6eKj2tefdo_I2Ls4-dfx1rAL0COR6FO5denb1i6p_ALxbqWM</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Cotrina-Luque, Jesús</creator><creator>Gil-Navarro, Maria Victoria</creator><creator>Acosta-García, Héctor</creator><creator>Alfaro-Lara, Eva Rocío</creator><creator>Luque-Márquez, Rafael</creator><creator>Beltrán-García, Margarita</creator><creator>Bautista-Paloma, Francisco Javier</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</title><author>Cotrina-Luque, Jesús ; Gil-Navarro, Maria Victoria ; Acosta-García, Héctor ; Alfaro-Lara, Eva Rocío ; Luque-Márquez, Rafael ; Beltrán-García, Margarita ; Bautista-Paloma, Francisco Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Bacterial Load</topic><topic>Cross Infection - diagnosis</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - microbiology</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Infections</topic><topic>Infusions, Intravenous</topic><topic>Internal Medicine</topic><topic>Intravenous therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Penicillanic Acid - administration & dosage</topic><topic>Penicillanic Acid - adverse effects</topic><topic>Penicillanic Acid - analogs & derivatives</topic><topic>Pharmacy</topic><topic>Piperacillin - administration & dosage</topic><topic>Piperacillin - adverse effects</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - growth & development</topic><topic>Pseudomonas aeruginosa - isolation & purification</topic><topic>Pseudomonas Infections - diagnosis</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Pseudomonas Infections - microbiology</topic><topic>Remission Induction</topic><topic>Research Article</topic><topic>Side effects</topic><topic>Spain</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cotrina-Luque, Jesús</creatorcontrib><creatorcontrib>Gil-Navarro, Maria Victoria</creatorcontrib><creatorcontrib>Acosta-García, Héctor</creatorcontrib><creatorcontrib>Alfaro-Lara, Eva Rocío</creatorcontrib><creatorcontrib>Luque-Márquez, Rafael</creatorcontrib><creatorcontrib>Beltrán-García, Margarita</creatorcontrib><creatorcontrib>Bautista-Paloma, Francisco Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cotrina-Luque, Jesús</au><au>Gil-Navarro, Maria Victoria</au><au>Acosta-García, Héctor</au><au>Alfaro-Lara, Eva Rocío</au><au>Luque-Márquez, Rafael</au><au>Beltrán-García, Margarita</au><au>Bautista-Paloma, Francisco Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</atitle><jtitle>International journal of clinical pharmacy</jtitle><stitle>Int J Clin Pharm</stitle><addtitle>Int J Clin Pharm</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>38</volume><issue>1</issue><spage>70</spage><epage>79</epage><pages>70-79</pages><issn>2210-7703</issn><eissn>2210-7711</eissn><abstract>Background
There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion.
Objective
The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to
Pseudomonas aeruginosa
.
Setting
Multicenter clinical trial with 11 third level Spanish hospitals.
Method
Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II).
Main outcome measure
Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported.
Results
78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported.
Conclusion
Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26474861</pmid><doi>10.1007/s11096-015-0208-y</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2210-7703 |
ispartof | International journal of clinical pharmacy, 2016-02, Vol.38 (1), p.70-79 |
issn | 2210-7703 2210-7711 |
language | eng |
recordid | cdi_proquest_miscellaneous_1792381530 |
source | Springer Nature |
subjects | Adult Aged Aged, 80 and over Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Bacterial Load Cross Infection - diagnosis Cross Infection - drug therapy Cross Infection - microbiology Double-Blind Method Drug Administration Schedule Drug therapy Female Humans Infections Infusions, Intravenous Internal Medicine Intravenous therapy Male Medicine Medicine & Public Health Middle Aged Penicillanic Acid - administration & dosage Penicillanic Acid - adverse effects Penicillanic Acid - analogs & derivatives Pharmacy Piperacillin - administration & dosage Piperacillin - adverse effects Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - growth & development Pseudomonas aeruginosa - isolation & purification Pseudomonas Infections - diagnosis Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology Remission Induction Research Article Side effects Spain Time Factors Treatment Outcome Young Adult |
title | Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T13%3A13%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20versus%20intermittent%20piperacillin/tazobactam%20infusion%20in%20infection%20due%20to%20or%20suspected%20pseudomonas%20aeruginosa&rft.jtitle=International%20journal%20of%20clinical%20pharmacy&rft.au=Cotrina-Luque,%20Jes%C3%BAs&rft.date=2016-02-01&rft.volume=38&rft.issue=1&rft.spage=70&rft.epage=79&rft.pages=70-79&rft.issn=2210-7703&rft.eissn=2210-7711&rft_id=info:doi/10.1007/s11096-015-0208-y&rft_dat=%3Cproquest_cross%3E3937133541%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1761208318&rft_id=info:pmid/26474861&rfr_iscdi=true |